1. Home
  2. SAGE vs ITIC Comparison

SAGE vs ITIC Comparison

Compare SAGE & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • ITIC
  • Stock Information
  • Founded
  • SAGE 2010
  • ITIC 1972
  • Country
  • SAGE United States
  • ITIC United States
  • Employees
  • SAGE N/A
  • ITIC N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • ITIC Specialty Insurers
  • Sector
  • SAGE Health Care
  • ITIC Finance
  • Exchange
  • SAGE Nasdaq
  • ITIC Nasdaq
  • Market Cap
  • SAGE 444.1M
  • ITIC 440.2M
  • IPO Year
  • SAGE 2014
  • ITIC N/A
  • Fundamental
  • Price
  • SAGE $7.50
  • ITIC $231.82
  • Analyst Decision
  • SAGE Hold
  • ITIC
  • Analyst Count
  • SAGE 20
  • ITIC 0
  • Target Price
  • SAGE $10.56
  • ITIC N/A
  • AVG Volume (30 Days)
  • SAGE 1.6M
  • ITIC 8.0K
  • Earning Date
  • SAGE 04-24-2025
  • ITIC 05-02-2025
  • Dividend Yield
  • SAGE N/A
  • ITIC 6.83%
  • EPS Growth
  • SAGE N/A
  • ITIC 43.49
  • EPS
  • SAGE N/A
  • ITIC 16.43
  • Revenue
  • SAGE $41,243,000.00
  • ITIC $258,298,000.00
  • Revenue This Year
  • SAGE $105.47
  • ITIC N/A
  • Revenue Next Year
  • SAGE $67.53
  • ITIC N/A
  • P/E Ratio
  • SAGE N/A
  • ITIC $14.11
  • Revenue Growth
  • SAGE N/A
  • ITIC 15.03
  • 52 Week Low
  • SAGE $4.62
  • ITIC $146.41
  • 52 Week High
  • SAGE $22.18
  • ITIC $290.40
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 60.15
  • ITIC 50.22
  • Support Level
  • SAGE $7.07
  • ITIC $229.62
  • Resistance Level
  • SAGE $7.64
  • ITIC $240.01
  • Average True Range (ATR)
  • SAGE 0.27
  • ITIC 3.69
  • MACD
  • SAGE 0.00
  • ITIC 0.33
  • Stochastic Oscillator
  • SAGE 78.74
  • ITIC 48.94

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About ITIC Investors Title Company

Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.

Share on Social Networks: